

Hydroxychloroquine: past, present, future

Lupus

7, 65-67

DOI: [10.1191/096120398678919886](https://doi.org/10.1191/096120398678919886)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Dermatologic lupus: Hopkins lupus cohort. <i>Seminars in Cutaneous Medicine and Surgery</i> , 1998, 17, 219-227.	1.6	30
2	Mast cell mediators other than histamine induced pruritus in atopic dermatitis patients - a dermal microdialysis study. <i>British Journal of Dermatology</i> , 2000, 142, 1079-1080.	1.4	8
3	Antiphospholipid antibody syndrome: the problems and the promise. <i>British Journal of Dermatology</i> , 2000, 142, 1080-1083.	1.4	8
4	Hydroxychloroquine-induced seizure in a patient with systemic lupus erythematosus. <i>Rheumatology International</i> , 2000, 20, 31-33.	1.5	19
5	Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. <i>Lupus</i> , 2000, 9, 170-175.	0.8	197
6	Should low-dose aspirin also be a background therapy for all patients with systemic lupus erythematosus (SLE)?. <i>Lupus</i> , 2000, 9, 561-562.	0.8	4
7	MANAGEMENT OF THROMBOSIS IN ANTIPHOSPHOLIPID ANTIBODY SYNDROME. <i>Rheumatic Disease Clinics of North America</i> , 2001, 27, 633-642.	0.8	28
8	Management of systemic lupus erythematosus (SLE). <i>Clinical and Experimental Allergy</i> , 2001, 31, 686-693.	1.4	8
9	Antimalarials—the “real” advance in lupus. <i>Lupus</i> , 2001, 10, 385-387.	0.8	73
10	A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. <i>British Journal of Rheumatology</i> , 2002, 41, 924-929.	2.5	295
11	Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. <i>Lupus</i> , 2002, 11, 71-81.	0.8	64
13	A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 719-727.	6.7	546
14	Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. <i>British Journal of Rheumatology</i> , 2003, 43, 202-205.	2.5	109
15	Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2004, 10, 89-126.	0.7	17
16	Erythromelalgia With Subsequent Digital Necrosis, Glomerulonephritis, and Antiphospholipid Antibodies. <i>Journal of Clinical Rheumatology</i> , 2005, 11, 209-212.	0.5	5
17	G-Rich DNA Suppresses Systemic Lupus. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3273-3280.	3.0	92
18	Optimal Use of Antimalarials in Treating Cutaneous Lupus Erythematosus. <i>American Journal of Clinical Dermatology</i> , 2005, 6, 1-11.	3.3	37
20	Hydroxychloroquine in lupus pregnancy. <i>Arthritis and Rheumatism</i> , 2006, 54, 3640-3647.	6.7	439

#	ARTICLE	IF	CITATIONS
21	Therapy of cutaneous lupus erythematosus. Expert Review of Dermatology, 2006, 1, 105-120.	0.3	2
22	Genetically determined mannan-binding lectin deficiency is of minor importance in determining susceptibility to severe infections and vascular organ damage in systemic lupus erythematosus. Lupus, 2007, 16, 245-253.	0.8	14
23	Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology, 2009, 48, 817-822.	0.9	99
24	Chapter 18 Difficult Clinical Situations in the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2009, 10, 215-234.	0.1	0
25	Effect of Medication on Microvascular Vasodilatation in Patients with Systemic Lupus Erythematosus. Basic and Clinical Pharmacology and Toxicology, 2010, 107, 919-924.	1.2	17
26	Vaccination and auto-immune rheumatic diseases. Current Opinion in Rheumatology, 2013, 25, 164-170.	2.0	9
27	Chronic Hydroxychloroquine Improves Endothelial Dysfunction and Protects Kidney in a Mouse Model of Systemic Lupus Erythematosus. Hypertension, 2014, 64, 330-337.	1.3	110
28	Clinical and financial burden of active lupus in Greece: a nationwide study. Lupus, 2016, 25, 1385-1394.	0.8	22
29	Atherosclerosis in Systemic Lupus Erythematosus. , 2001, , 255-265.		5
30	Management of the Difficult Aspects of the Antiphospholipid Syndrome. , 2002, , 395-407.		2
31	IgA Anticardiolipin and Anti-β ₂ -Glycoprotein I Are the Most Prevalent Isotypes in African American Patients with Systemic Lupus Erythematosus. American Journal of the Medical Sciences, 1999, 318, 55.	0.4	70
32	ANTIMALARIAL DRUGS IN THERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS: PAST, PRESENT, FUTURE. Sovremennaya Revmatologiya, 2010, .	0.1	0
33	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2110730.	1.2	52